Related Experiment Video
Updated: Jul 12, 2026
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Treatment for the procoagulant state in type 2 diabetes
1Department of Medicine, Diabetes Center, Medical University of South Carolina, Charleston, South Carolina, USA. colwelja@musc.edu
Abstract:
A procoagulant state has been found to exist in diabetes mellitus. There may be activation of the intrinsic coagulation system, decreased fibrinolytic activity, or alterations in platelet function. Intensive glycemic control with insulin is effective in reducing the impact of this procoagulant state by favorably affecting all three components of the system. Decreased fibrinolytic activity, as influenced by plasma PAI-1 levels, may be favorably affected by weight loss, exercise, a low-GI diet, or by metformin, thiazolidinediones, gemfibrozil, and ACE inhibitor therapy. Insulin has variable effects on plasma PAI-1 activity. Estrogens will lower the elevated PAI-1 levels seen in the menopausal state. Collaborative trial evidence supports the use of low-dose aspirin as a primary or secondary prevention strategy in diabetic persons who are at high cardiovascular risk. A recent study suggests that this category includes virtually every type 2 diabetic individual in the United States. The American Diabetes Association recommends enteric-coated aspirin, 81 to 325 mg/day, as the first choice. In the case of aspirin allergy, clopidrogel is an alternate choice. Thus, recognition of and therapy for a procoagulant state in diabetes mellitus is likely to result in a decrease in the atherothrombotic events that characterize the later stages of this disease.
Insights
Diabetes mellitus is linked to a procoagulant state, increasing atherothrombotic risk. Intensive glycemic control and aspirin therapy are key strategies to mitigate these risks in diabetic patients.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Hematology
Background:
- Diabetes mellitus is associated with a procoagulant state, characterized by intrinsic coagulation system activation, reduced fibrinolysis, and altered platelet function.
- This procoagulant state contributes to the increased risk of atherothrombotic events in diabetic individuals.
Purpose of the Study:
- To review the procoagulant state in diabetes mellitus.
- To discuss therapeutic strategies for mitigating atherothrombotic risk in diabetic patients.
Main Methods:
- Review of existing literature on coagulation, fibrinolysis, and platelet function in diabetes.
- Analysis of evidence for interventions including glycemic control, lifestyle modifications, pharmacotherapy, and antiplatelet agents.
Main Results:
- Intensive glycemic control with insulin positively impacts coagulation, fibrinolysis, and platelet function.
- Weight loss, exercise, diet, metformin, thiazolidinediones, gemfibrozil, ACE inhibitors, and estrogens can improve fibrinolytic activity by affecting plasma PAI-1 levels.
- Low-dose aspirin (81-325 mg/day) is recommended for primary or secondary cardiovascular risk prevention in most type 2 diabetic patients, with clopidogrel as an alternative for aspirin-allergic individuals.
Conclusions:
- Managing the procoagulant state in diabetes mellitus through glycemic control, lifestyle changes, and appropriate pharmacotherapy, including aspirin, is crucial for reducing atherothrombotic events.
- Therapeutic strategies targeting coagulation, fibrinolysis, and platelet function can significantly improve cardiovascular outcomes in diabetic patients.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Type I Diabetes II: Pathophysiology
01:26Type II Diabetes I: Introduction
01:24Type II Diabetes II: Pathophysiology
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis